User profiles for S Aebi
Stefan AebiMedical Oncology, Cancer Center Lucerne Cantonal Hospital, and University of Berne Verified email at onkologie.ch Cited by 10839 |
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
…, MM Regan, HJ Senn, EP Winer, M Gnant, S Aebi… - Annals of oncology, 2021 - Elsevier
… However, the Panel strongly favored RNI for patients who initially presented with a clinically
positive axillary node(s), even when such patients achieve a pCR with neoadjuvant therapy. …
positive axillary node(s), even when such patients achieve a pCR with neoadjuvant therapy. …
The role of DNA mismatch repair in drug resistance.
D Fink, S Aebi, SB Howell - Clinical cancer research: an official journal of the …, 1998 - AACR
Loss of DNA mismatch repair (MMR) has been observed in a variety of human cancers. In
addition to predisposing to oncogenesis, loss of MMR activity is of concern with respect to the …
addition to predisposing to oncogenesis, loss of MMR activity is of concern with respect to the …
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
… S Gelber and RD Gelber were responsible or the statistical analysis. J Collins was the
chairman of … S Aebi wrote the first draft of the report. All investigators read and edited the report. …
chairman of … S Aebi wrote the first draft of the report. All investigators read and edited the report. …
The role of DNA mismatch repair in platinum drug resistance
D Fink, S Nebel, S Aebi, H Zheng, B Cenni, A Nehmé… - Cancer research, 1996 - AACR
Loss of DNA mismatch repair occurs in many types of tumors. The effect of the loss of DNA
mismatch repair activity on sensitivity to cisplatin and a panel of analogues was tested using …
mismatch repair activity on sensitivity to cisplatin and a panel of analogues was tested using …
Loss of DNA mismatch repair in acquired resistance to cisplatin
S Aebi, B Kurdi-Haidar, R Gordon, B Cenni, H Zheng… - Cancer research, 1996 - AACR
Selection of cells for resistance to cisplatin, a well-recognized mutagen, could result in
mutations in genes involved in DNA mismatch repair and thereby to resistance to DNA-alkylating …
mutations in genes involved in DNA mismatch repair and thereby to resistance to DNA-alkylating …
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised …
…, F Boyle, G Jerusalem, R Stahel, S Aebi… - The Lancet …, 2018 - thelancet.com
Background We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial
comparing disease-free survival in patients with breast cancer with one or more micrometastatic (…
comparing disease-free survival in patients with breast cancer with one or more micrometastatic (…
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
…, B Ruepp, F Boyle, R Stahel, S Aebi… - The Lancet …, 2019 - thelancet.com
Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate.
We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be …
We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be …
[HTML][HTML] Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Background Male breast cancer (BC) is rare, managed by extrapolation from female BC. The
International Male BC Program aims to better characterize and manage this disease. We …
International Male BC Program aims to better characterize and manage this disease. We …
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Aebi, T Davidson, G Gruber… - Annals of oncology, 2011 - annalsofoncology.org
… The presence and sizes of the smaller tumor(s) should be recorded using the ‘(m)’ modifier.
… The presence and sizes of the smaller tumor(s) should be recorded using the ‘(m)’ modifier. …
… The presence and sizes of the smaller tumor(s) should be recorded using the ‘(m)’ modifier. …
In Vitro and in Vivo Resistance to Cisplatin in Cells That Have Lost DNA Mismatch Repair
D Fink, H Zheng, S Nebel, PS Norris, S Aebi, TP Lin… - Cancer research, 1997 - AACR
In vitro studies have shown that loss of DNA mismatch repair due to lack of either hMSH2 or
hMLH1 activity results in low-level resistance to cisplatin but not to oxaliplatin, an analogue …
hMLH1 activity results in low-level resistance to cisplatin but not to oxaliplatin, an analogue …